lp 1

Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.

LP 130 is an inhibitor of retroviral protease.

NLP 1 is a DNA intercalating hypoxic cell radiosensitizer and cytotoxin.

LP 12 hydrochloride is a selective 5-HT7 receptor agonist (Ki=0.13 nM). LP 12 hydrochloride is selective for 5-HT7 over D2, 5-HT1A, and 5-HT2A receptors (Ki values of 224 nM, 60.9 nM, and >1000 nM, respectively).

LP 12 hydrochloride hydrate is a selective and potent agonist at the 5-HT7 receptor (Ki: 0.13 nM) and is more selective for the 5-HT7 receptor than the D2 receptor (Ki: 224 nM), 5-HT1A receptor (Ki: 60.9 nM), and 5-HT2A receptor (Ki: >1000 nM).

Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.

LP-922761 is a potent, selective, and orally active AAK1 inhibitor with inhibitory effects on BMP-2 induced protein kinase (BIKE).

1-Linoleoyl Glycerol (Monolinolein) is fatty acid glycerol that has been isolated from Saururus Chinensis roots. The (R)-1-Linoleoyl Glycerol and (S)-1-Linoleoyl Glycerol exhibit Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitory activities with IC50 values of 45.0 and 52.0 μM, respectively.

LP-533401 is an inhibitor of Tryptophan hydroxylase 1. It is used for regulates serotonin production in the gut.

LP-533401 hydrochloride is a peripheral Tph inhibitor that cannot cross the blood-brain barrier that inhibits 5-hydroxytryptamine synthesis and can be used to study periodontal disease and hepatic steatosis.

LP-935509 is a selective, brain-permeable, small molecule competitive inhibitor of articulin-2-associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM. LP-935509 is a potent inhibitor of BIKE (IC50 of 14 nM) and a moderate inhibitor of GAK (IC50 of 320±40 nM).

SKQ1, also known as Visomitin or plastoquinonyl decyltriphenyl phosphonium (PDTP), is a potent mitochondrial-targeted antioxidant. As the active pharmaceutical ingredient (API) in Visomitin eye drops, SKQ1 exhibits various biomedical activities: (1) prevents impairment of long-term potentiation in rat hippocampal slices caused by amyloid β-protein; (2) reverses aging-related biomarkers in rats; (3) slows age-related degenerative changes in the retinas and choroid of Wistar and OXYS rats; (4) extends the lifespan of male rodents in LP or SPF conditions. SKQ1 can penetrate cell membranes and is proposed for use in anti-aging therapies. Clinical trials for SKQ1 are currently underway in Russia to treat glaucoma. For convenience, SKQ1 is provided as an ethanol-water (1:1, v v) solution at a concentration of 200 mg mL.

LP-284 is a potent DNA alkylating agent that kills solid tumors and can be used in hematologic cancer studies with compromised DNA repair, such as mantle cell lymphoma (MCL) [1] [2].

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme catalyzes the hydrolysis of lipoprotein lipids or phospholipids. The compound has research potential in neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

OUN10989, an analogue compound of LP-261, is a Potent Antimitotic Agent. OUN10989 exhibited potent inhibition of mitosis at the G2 M stage. OUN10989 was first reported in J. Med. Chem 54(1), 179-200; 2011 (compound 7). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https: www.medkoo.com page naming).

SB-435495 hydrochloride is a potent, selective, reversible, non-covalent, and orally active inhibitor of Lp-PLA2, with an IC50 of 0.06 nM [1] [3].

SB-435495 ditartrate is a potent, selective, reversible, non-covalent, and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM [1] [3].

Pep19-2.5, a synthetic antitoxin peptide, inhibits the intracellular signaling cascade triggered by endotoxins by blocking the activity of lipopeptides (LP) and lipopolysaccharides (LPS) mediated through both transmembrane and cytosolic pattern recognition receptors (PRRs). This action disrupts the signaling pathways that normally result in inflammation and cell pyroptosis [1].

Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is used in research on neurodegenerative diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions like atherosclerosis [1].

Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, shows promise for neurodegenerative disease research [1].

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4 and is applicable in research on neurodegenerative disorders including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

Lp-PLA2-IN-15 (example 2) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), showing potential for research in Alzheimer's disease [1].

Lp-PLA2-IN-16 (Example 1) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in Alzheimer's disease research [1].

Lp-PLA2-IN-17 (Compound 39) acts as an inhibitor of Lp-PLA 2. It is utilized in research to explore disorders associated with the hydrolysis of oxidized lipids into two inflammatory substances mediated by Lp-PLA 2 [1].